Discounted Cash Flow Rating

Neutral

Return on Equity Rating

Sell

Debt to Equity Rating

Neutral

Price to Earnings Rating

Strong Sell

Analyst Rating

Neutral

Simple Moving Average

Strong Sell

Exponential Moving Average

Strong Sell

Relative Strength Index

Buy

Standard Deviation

Strong Buy

Williams %R

Strong Buy

Average Directional Index

Neutral

Insider Trading

Neutral

Wall Street Data Solutions Rating

Neutral

B

Tarsus Pharmaceuticals, Inc. Common Stock (TARS)

Biological Products, (no Disgnostic Substances)

https://www.tarsusrx.com

Tarsus Pharmaceuticals Inc is a late clinical-stage biopharmaceutical company. It is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's lead candidate TP-03 is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.

15440 LAGUNA CANYON ROAD
IRVINE, CA

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

10/16/2020

Market Cap

965,117,929

Shares Outstanding

33,110,000

Weighted SO

33,104,612

Total Employees

N/A

Upcoming Earnings

08/08/2024

Similar Tickers

LIAN --.--%

ALDX --.--%

TVTX --.--%

ETON --.--%

CNTB --.--%

ABOS --.--%

NUVB --.--%

ELDN --.--%

OPT --.--%

Beta

1.0580

Last Div

0.0000

Range

12.57-42.5

Chg

-1.5900

Avg Vol

744008

Mkt Cap

965117929

Exch

NASDAQ

Country

US

Phone

949 409 9820

DCF Diff

19.2724

DCF

6.4126

Div Yield

0.0000

P/S

11.5758

EV Multiple

-5.4961

P/FV

3.8041

Div Yield %

0.0000

P/E

-6.3941

PEG

0.0767

Payout

0.0000

Current Ratio

7.0309

Quick Ratio

6.9883

Cash Ratio

3.5116

DSO

135.0177

DIO

128.1675

Op Cycle

263.1852

DPO

1556.2862

CCC

-1293.1010

Gross Margin

0.9250

Op Margin

-1.8755

Pretax Margin

-1.8214

Net Margin

-1.8000

Eff Tax Rate

-0.1866

ROA

-0.3982

ROE

-0.6399

ROCE

-0.4807

NI/EBT

0.9882

EBT/EBIT

0.9711

EBIT/Rev

-1.8755

Debt Ratio

0.1915

D/E

0.2862

LT Debt/Cap

0.2210

Total Debt/Cap

0.2225

Int Coverage

52.8102

CF/Debt

-1.7163

Equity Multi

1.4940

Rec Turnover

2.7033

Pay Turnover

0.2345

Inv Turnover

2.8478

FA Turnover

19.8038

Asset Turnover

0.2212

OCF/Share

-3.2755

FCF/Share

-3.3175

Cash/Share

8.5551

OCF/Sales

-1.4860

FCF/OCF

1.0128

CF Coverage

-1.7163

ST Coverage

-204.7769

CapEx Coverage

-78.0164

Div&CapEx Cov

-78.0164

P/BV

3.8041

P/B

3.8041

P/S

11.5758

P/E

-6.3941

P/FCF

-7.6915

P/OCF

-7.7454

P/CF

-7.7454

PEG

0.0767

P/S

11.5758

EV Multiple

-5.4961

P/FV

3.8041

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Mar 13, 01:49 Tarsus Announces Pricing of Upsized $125.0 Million Public Offering GlobeNewswire Inc. Mar 06, 22:00 Tarsus to Participate in Upcoming Investor Conference GlobeNewswire Inc. Nov 01, 18:35 Tarsus to Report Third Quarter 2023 Financial Results on Thursday, November 9, 2023 GlobeNewswire Inc. Nov 01, 18:35 Tarsus to Report Third Quarter 2023 Financial Results on Thursday, November 9, 2023

Revenue Product Segmentation